Pretreatment BRAF V600E positivity and structural recurrence risk after radiofrequency ablation for cT1N0M0 papillary thyroid carcinoma: a retrospective cohort study
This retrospective cohort study of 433 patients with cT1N0M0 papillary thyroid carcinoma suggests that while BRAF V600E positivity is associated with a higher risk of structural recurrence after radiofrequency ablation, it should not serve as an absolute exclusion criterion but rather as a factor to guide patient counseling and follow-up intensity.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For decades, the standard response to a small, early-stage thyroid cancer was to remove the thyroid gland surgically. However, as medical imaging has become more sensitive, doctors now find many tiny tumors that grow so slowly they may never cause harm. This discovery has shifted the approach from immediate surgery to a more nuanced strategy, where patients might be watched closely, or treated with a less invasive method called radiofrequency ablation. In this procedure, a thin needle is inserted into the tumor under ultrasound guidance, and heat is used to destroy the cancer cells while leaving the rest of the thyroid intact. The question facing doctors today is how to decide who is a good candidate for this heat treatment. One specific genetic marker, known as BRAF V600E, has long been associated with more aggressive behavior in thyroid cancer when patients undergo surgery. Because of this link, many clinicians hesitate to use radiofrequency ablation on patients who carry this marker, fearing the cancer might return. A new study from China seeks to clarify whether this genetic flag should automatically disqualify a patient from the heat treatment or if it simply signals a need for closer monitoring.
Researchers at the China-Japan Friendship Hospital set out to investigate this question by looking back at the records of 433 patients who had already undergone radiofrequency ablation for small, early-stage thyroid cancer. Every patient in this group had a test done before the procedure to see if their tumor carried the BRAF V600E mutation. The team split the group into two categories: those with the mutation and those without. They then followed these patients for a median of about 14 months, using ultrasound scans to check for any signs that the cancer had returned or spread to nearby lymph nodes. The goal was to see if the presence of the mutation predicted a higher chance of the cancer coming back after the heat treatment.
The results offered a clear, though cautious, picture. During the follow-up period, only three patients in the entire group of 433 experienced a structural recurrence or metastasis. Crucially, all three of these events occurred in patients who had the BRAF V600E mutation. None of the patients without the mutation saw their cancer return. This suggests that while the mutation is present in about half of the patients who received the treatment, it is indeed linked to the rare instances where the cancer was not fully controlled. However, the study also found that the overall rate of recurrence was extremely low, even for those with the mutation. The researchers noted that the number of events was too small to draw a definitive, hard-and-fast rule, but the pattern was consistent: the risk was concentrated entirely in the group with the genetic marker.
Beyond the recurrence rates, the team examined whether the mutation made the procedure itself more dangerous or difficult. They looked at complications, such as nerve injury or bleeding, and found no difference between the two groups. Patients with the mutation did not suffer more side effects than those without it. They also analyzed the physical characteristics of the tumors, such as their location and how close they were to sensitive structures like the windpipe or nerves. They found that the recurrence events were not clustered in the most physically complex or difficult-to-treat tumors. Instead, the genetic marker appeared to be the primary factor distinguishing the patients who experienced a return of the disease.
The study concludes that the presence of the BRAF V600E mutation should not be treated as an automatic reason to deny a patient radiofrequency ablation. While the mutation identifies a subgroup where recurrences occurred, the absolute risk remains very low. The authors suggest that rather than using the genetic test as a strict gatekeeper to exclude patients, doctors should use the result to guide the conversation with the patient. For those with the mutation, the treatment remains a viable option, but it should come with a commitment to more rigorous and frequent follow-up scans to catch any potential return of the cancer early. In this way, the genetic information serves as a tool for tailoring surveillance rather than a barrier to treatment.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.